Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

Item
http://www.wikidata.org/entity/Q28277143
MAO-inhibitors in Parkinson's DiseaseApomorphine and the dopamine hypothesis of schizophrenia: a dilemma?Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.How to optimize the treatment of early stage Parkinson's disease.Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.Arterial hypertension, a tricky side of Parkinson's disease: physiopathology and therapeutic features.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Changes in vascular alpha 1- and alpha 2-adrenoceptor responsiveness by selegiline treatment.Selegiline enhances erectile activity induced by dopamine injection in the paraventricular nucleus of the hypothalamus in anesthetized rats.N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic CEarly (Uncomplicated) Parkinson's Disease
P2860

Safety of selegiline (deprenyl) in the treatment of Parkinson's disease

Item
http://www.wikidata.org/entity/Q28277143
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@ast
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@nl
type
label
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@ast
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@nl
altLabel
Safety of Selegiline (Deprenyl) in the Treatment of Parkinson??s Disease
@en
prefLabel
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@ast
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@nl
P1433
P1476
P2093
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
Safety of selegiline (deprenyl) in the treatment of Parkinson's disease
@en
P2093
P2888
P304
P31
P356
10.2165/00002018-199819010-00002
P407
P433
P478
P577
P6179
P698
P921